文献速递药物不良反应与药物警戒

多发性硬化疾病修正治疗药物与癌症报告风险:基于FDA不良事件报告系统的失衡分析

Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: A disproportionality analysis using the US Food and Drug Administration Adverse Event Reporting System database.
PubMed 文献 · Br J Clin Pharmacol · 2021-06-02

本研究利用FDA不良事件报告系统2004至2020年数据,以干扰素β-1a为参照,计算多发性硬化疾病修正治疗药物报告癌症的粗报告比值比和调整报告比值比。结果显示获批药物均未检测到癌症风险增加的安全信号,但敏感性分析中干扰素β-1a和重组人干扰素β-1a及阿仑单抗出现潜在信号,需进一步评估。

要点

  • 以干扰素β-1a为参照,多数疾病修正治疗药物报告恶性肿瘤的调整报告比值比低于1。
  • 敏感性分析以其余药物为参照时,干扰素β-1a和聚乙二醇干扰素β-1a调整报告比值比分别为2.60和1.47。
  • 获批疾病修正治疗药物未检测到癌症风险增加的安全信号,但部分潜在信号需进一步验证。

核心结论

  • 获批的多发性硬化疾病修正治疗药物未检测到癌症风险增加的安全信号。
  • 敏感性分析中干扰素β-1a、聚乙二醇干扰素β-1a和阿仑单抗出现潜在安全信号,需更稳健证据进一步评估。

研究设计与样本

  • 基于FDA不良事件报告系统2004至2020年数据的失衡分析。
  • 以干扰素β-1a为参照药物,计算癌症的粗报告比值比和调整报告比值比。
  • 敏感性分析考察多重注册疾病修正治疗药物报告组、适应症限制效应及以其余药物为参照的结果。

主要发现

  • 调整年龄、性别和合并用药后,恶性肿瘤的调整报告比值比(95%CI)为:克拉屈滨0.46(0.18-0.95)、富马酸二甲酯0.30(0.27-0.34)、芬戈莫德0.61(0.53-0.70)、格拉替雷0.50(0.43-0.58)、阿仑单抗0.84(0.64-1.08)、干扰素β-1b 0.49(0.42-0.56)、那他珠单抗0.36(0.34-0.39)、奥瑞珠单抗0.48(0.29-0.74)、聚乙二醇干扰素β-1a 0.35(0.26-0.48)、西尼莫德0.89(0.47-1.54)、特立氟胺0.25(0.21-0.30)。
  • 敏感性分析以其余药物为参照时,干扰素β-1a调整报告比值比2.60(2.47-2.74,P < .001),聚乙二醇干扰素β-1a调整报告比值比2.60(2.47-2.74,P < .001),阿仑单抗调整报告比值比1.47(1.13-1.88,P = .003)。

临床怎么用

  • 临床处方多发性硬化疾病修正治疗药物时,当前证据未提示癌症报告风险整体增加。
  • 对使用干扰素β-1a、聚乙二醇干扰素β-1a或阿仑单抗的患者,可关注癌症相关症状但不应据此改变治疗决策。

局限性

  • 研究基于自发报告数据库,存在报告偏倚和适应症混杂等固有局限。
  • 敏感性分析中的潜在信号需更稳健证据进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: While the efficacy of disease-modifying therapies (DMTs) for patients with multiple sclerosis (MS) is established, little is known about their long-term safety. Cancer-risk after DMT use remains unclear. This study aimed to investigate whether the prescription of DMTs for patients with MS increases the risk of reporting cancer. METHODS: Data from the Food and Drug Administration Adverse Event Reporting System were extracted from 2004 to 2020. After data cleaning, the crude and adjusted reported odds ratios (cROR and aROR) for cancer were calculated for DMTs with Interferon beta-1a as the reference drug. Sensitivity analyses investigated the group of reports with multiple registered DMTs, the effect of indication restriction and the results when using the rest of the DMTs as reference. RESULTS: For malignant tumours, aROR (95% confidence interval [CI]) values were Cladribine 0.46 (0.18-0.95), Dimethyl fumarate 0.30 (0.27-0.34), Fingolimod 0.61 (0.53-0.70), Glatiramer 0.50 (0.43-0.58), Alemtuzumab 0.84 (0.64-1.08), Interferon beta-1b 0.49 (0.42-0.56), Natalizumab 0.36 (0.34-0.39), Ocrelizumab 0.48 (0.29-0.74), Peginterferon beta-1a 0.35 (0.26-0.48), Siponimod 0.89 (0.47-1.54) and Teriflunomide 0.25(0.21-0.30) adjusted to age, gender and concomitant medications. In the sensitivity analysis, when the rest of the drugs were used as a reference, Interferon beta-1a and Peginterferon beta-1a had aROR (95% CI) 2.60 (2.47-2.74, P < .001) and Alemtuzumab had aROR 1.47 (1.13-1.88, I = .003). CONCLUSIONS: No safety signal for increased cancer risk was detected among the approved DMTs. A potential safety signal detected in the sensitivity analysis concerning Interferon beta-1a and Alemtuzumab requires further evaluation with more robust evidence.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Stamatellos VP, Siafis S, Papazisis G, et al. Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: A disproportionality analysis using the US Food and Drug Administration Adverse Event Reporting System database. Br J Clin Pharmacol. 2021. PMID: 33998034. doi:10.1111/bcp.14916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。